Effect of alprenolol and alprenolol in combination with saluretics in hypertension.
D000328:Adult; D000368:Aged; D000526:Alprenolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001581:Benzothiadiazines; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D012131:Respiratory Insufficiency / Q000139:chemically induced; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides; D013997:Time Factors; D014527:Uric Acid / Q000097:blood
D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D013449:Sulfonamides; D014527:Uric Acid; D000526:Alprenolol; D011188:Potassium